AngioDynamics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended November 30, 2012; Provides Earnings Guidance for the Full Year of 2013
For the six months, net sales were $170,423,000 against $112,530,000 a year ago. Operating income was $5,806,000 against $6,643,000 a year ago. Income before income taxes was $1,978,000 against $5,672,000 a year ago. Net income was $1,248,000 or $0.04 per basic and diluted share against $3,702,000 or $0.15 per basic and diluted share a year ago. Adjusted net income was $7,164,000 or $0.20 per diluted share against $3,658,000 or $0.14 per diluted share a year ago. EBITDA was $17,967,000 or $0.51 per diluted share against $12,916,000 or $0.51 per diluted share a year ago. Adjusted EBITDA was $27,010,000 or $0.77 per diluted share against $12,872,000 or $0.51 per basic and diluted share a year ago. Adjusted operating income was $14,849,000 against $6,599,000 a year ago. Net cash provided by operating activities was $5,515,000 against $5,713,000 a year ago. Additions to property, plant and equipment was $4,787,000 against $1,058,000 a year ago.
For the full year of 2013, the company expects to report sales between $355 million to $360 million, gross margin between $50% to 51%, operating income between $29 million to $31 million, EBITDA between $56 million to $57 million and EPS between $0.40 to 0.42.